A Study of the Treatment of Rett Syndrome With Folate and Betaine
- 18 February 2009
- journal article
- other
- Published by SAGE Publications in Journal of Child Neurology
- Vol. 24 (5) , 551-556
Abstract
We tested the hypothesis that increasing methyl-group pools might promote transcriptional repression by other methyl-binding proteins or by mutant methyl-CpG-binding protein 2 with altered affinity, ameliorating the clinical features of Rett syndrome. A 12-month, double-blind, placebo-controlled folate—betaine trial enrolled 73 methylCpG-binding protein 2 mutation positive female participants meeting consensus criteria for Rett syndrome. Participants were randomized as young (< age 5 years) or old (! age 5 years). Structured clinical assessments occurred at baseline, 3, 6, and 12 months. Primary outcome measures included quantitative evaluation of breathing and hand movements during wakefulness, growth, anthropometry, motor/behavioral function, and qualitative evaluations from electroencephalograms and parent questionnaires. In all, 68 participants completed the study. Objective evidence of improvement was not found. Subjective improvement from parent questionnaires was noted for the <5 years group. This study should inform future treatment trials regarding balancing participants with specific mutations and comparable severity to minimize selection bias.Keywords
This publication has 17 references indexed in Scilit:
- Specific mutations in Methyl-CpG-Binding Protein 2 confer different severity in Rett syndromeNeurology, 2008
- Investigating genotype–phenotype relationships in Rett syndrome using an international data setNeurology, 2008
- Phenotypic manifestations of MECP2 mutations in classical and atypical rett syndromeAmerican Journal of Medical Genetics Part A, 2003
- An update on clinically applicable diagnostic criteria in Rett syndromeEuropean Journal of Paediatric Neurology, 2002
- The biological functions of the methyl-CpG-binding protein MeCP2 and its implication in Rett syndromeBrain and Development, 2001
- MeCP2 Is a Transcriptional Repressor with Abundant Binding Sites in Genomic ChromatinCell, 1997
- Rett syndrome: Controlled study of an oral opiate antagonist, naltrexoneAnnals of Neurology, 1994
- Extrapyramidal involvement in Rett's syndromeNeurology, 1990
- Demyelination and decreased S ‐adenosylmethionine in 5.10‐methylenetetrahydrofolate reductase deficiencyNeurology, 1988
- Folic acid—an innocuous means to reduce plasma homocysteineScandinavian Journal of Clinical and Laboratory Investigation, 1988